Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Pulmonary Disease, Chronic Obstructive 1Pneumonia 1

Interventions

pembrolizumab 70Nivolumab 24Docetaxel 17Cisplatin 15Paclitaxel 13Carboplatin 12Gemcitabine 8Cetuximab 8Ipilimumab 7durvalumab 6avelumab 6atezolizumab 6Radiotherapy 6Cyclophosphamide 6spartalizumab 5Trastuzumab 5Taxes 5Pemetrexed 5Erlotinib Hydrochloride 5tremelimumab 4cemiplimab 4Specimen Handling 4Leucovorin 4Interleukin-2 4Fluorouracil 4Capecitabine 4Biopsy 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4utomilumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × CIMAvax EGF × Thoracic × Clear all
NCT02955290 2025-11-10

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
51 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡